cas12229-sup-0001-TableS1.xlsapplication/msexcel28KTable S1. Immunohistochemistry results for basal markers.
cas12229-sup-0002-TableS2.xlsapplication/msexcel28KTable S2. Differences in averaged proportions of phosphatidylinositols (PIs) (Malignant- vs benign-region).
cas12229-sup-0003-TableS3.xlsapplication/msexcel21KTable S3. Differences in signal intensities during the progression.
cas12229-sup-0004-FigS1.tifimage/tif2205KFig. S1. Mass spectrometry (MS)/MS spectra of phosphatidylinositols (PIs) observed in this study.
cas12229-sup-0005-FigS2.tifimage/tif2036KFig. S2. The averaged mass spectra obtained from epithelial areas in breast cancer tissues.
cas12229-sup-0006-FigS3.tifimage/tif1864KFig. S3. The averaged mass spectra obtained from stromal areas in breast cancer tissues.
cas12229-sup-0007-FigS4.tifimage/tif3422KFig. S4. Mass spectrometry (MS) images of PI (18:0/20:4) in the same case of Fig. 5.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.